Active ingredients: acalabrutinib
What it is used for
CALQUENCE is indicated for the treatment of patients with mantle cell lymphoma who have received at least one prior therapy.,CALQUENCE is indicated for the treatment of patients with mantle cell lymphoma who have received at least one prior therapy.,CALQUENCE is indicated for the treatment of patients with chronic lymphocytic leukaemia(CLL)/small lymphocytic lymphoma (SLL).
How to take it
The way to take this medicine is: Oral. This medicine is taken by mouth.
- Store below 30 degrees Celsius
- Shelf lifetime is 3 Years.
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
Size 1 hard gelatin capsule with a yellow body and blue cap, marked in black ink with ACA 100 mg
Images are the copyright of the Pharmacy Guild of Australia
Do I need a prescription?
This medicine is available from a pharmacist and requires a prescription. It is
Is this medicine subsidised?
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on May 1, 2022. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
Pregnant or planning a pregnancy?
For the active ingredient acalabrutinib
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Consumer Medicines Information (CMI)
For side effects, taking other medicines and more
Reporting side effects
This medicine is under additional monitoring as it is new or being used in a different way. You can help identify new safety information by reporting any side effects you may get.